Prognostic factors in the acute lymphoid and myeloid leukemias of infants

Leukemia

Volumn 10, Issue 6, 1996, Pages 952-956

  Pui, C H ^a,b   Ribeiro, R C ^a,b   Campana, D ^a,b   Raimondi, S C ^a,b   Hancock, M L ^a   Behm, F G ^a,b   Sandlund, J T ^a,b   Rivera, G K ^a,b   Evans, W E ^a   Crist, W M ^a,b   Krance, R ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

11q23 chromosomal rearrangements; Acute lymphoblastic leukemia; Acute myeloid leukemia; Infants; Male sex; MLL rearrangements

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; AGE; ARTICLE; CANCER CHEMOTHERAPY; CELL GROWTH; CHILDHOOD LEUKEMIA; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CYTOGENETICS; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; STROMA CELL; TREATMENT OUTCOME;

EID: 8944238470     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Pui C-H, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia 1995; 9: 762-769.
2. Reaman G, Zeltzer P, Bleyer WA, Amendola B, Level C, Sather H, Hammond D. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Childrens Cancer Study Group. J Clin Oncol 1985; 3: 1513-1521.
3. Crist W, Pullen J, Boyett J, Falletta J, van Eys J, Borowitz M, Jackson J, Dowell B, Frankel L, Quddus F, Ragab A, Vietti T. Clinical and biologic features predict a poor prognosis in acute lymphoid leukemias in infants: a Pediatric Oncology Group study. Blood 1986; 67: 135-140.
4. Leverger G, Bancillon A, Schaison G, Alby N, Boiron M. Acute lymphoblastic leukemia in very young children. Diagnostic and therapeutic aspects of 43 cases. Am J Pediatr Hematol Oncol 1986; 8: 213-219.
5. Reaman GH, Steinherz PG, Gaynon PS, Bleyer WA, Finkelstein JZ, Evans R, Miller DR, Sather HN, Hammond GD. Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Cancer Treat Rep 1987; 71: 1033-1038.
6. Ishii E, Okamura J, Tsuchida M, Kobayashi M, Akiyama Y, Nakahata T, Kojima S, Hanada R, Horibe K, Sato T, Komada Y, Kimura K, Sakaguchi C, Hosoya R, Oda M, Tsunematsu Y, Kawa K, Konishi S, Tsukimoto I, Matsuyama K, Udea K. Infant leukemia in Japan: clinical and biological analysis of 48 cases. Med Pediatr Oncol 1991; 19: 28-32.
7. Eden OB, Shaw MP, Lilleyman JS, Richards S. Children under two years treated according to the Medical Research Council UKALL VIII study and trial 1980-1984 (on behalf of the Medical Research Council Working Party on Leukaemia in Childhood). Br J Cancer 1992; 66 (Suppl. XVIII): S58-S62.
8. Chessells JM. Leukaemia in the young child. Br J Cancer 1992; 66 (Suppl. XVIII): S54-S57.
9. Ferster A, Bertrand Y, Benoit Y, Boilletot A, Behar C, Margueritte G, Thyss A, Robert A, Mazingue F, Souillet G, Philippe N, Solbu G, Suciu S, Otten J. Improved survival for acute lymphoblastic leukaemia in infancy: the experience of EORTC-Childhood Leukaemia Cooperative Group. Br J Haematol 1994; 86: 284-290.
10. Pui C-H, Behm FG, Downing JR, Hancock ML, Shurtleff SA, Ribeiro RC, Head DR, Mahmoud HH, Sandlund JT, Furman WL, Roberts WM, Crist WM, Raimondi SC. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 1994; 12: 909-915.
11. Basso G, Putti MC, Cantú-Rajnoldi A, Saitta M, Santostasi T, Santoro N, Lippi A, Comelli A, Felici L, Favre C, Mancuso GR, Guglielmi C, Paolucci P, Biondi A. The immunophenotype in infant acute lymphoblastic leukaemia: correlation with clinical outcome. An Italian multicentre study (AIEOP). Br J Haematol 1992; 81: 184-191.
12. Chessells JM, Eden OB, Bailey C, Lilleyman JS, Richards SM. Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials: report from the Medical Research Council Working Party on Childhood Leukaemia. Leukemia 1994; 8: 1275-1279.
13. Pui C-H, Rivera GK, Hancock ML, Raimondi SC, Sandlund JT, Mahmoud HH, Ribeiro RC, Furman WL, Hurwitz CA, Crist WM, Behm FG. Clinical significance of CD10 expression in childhood acute lymphoblastic leukemia. Leukemia 1993; 7: 35-40.
14. Ludwig W-D, Bartram CR, Harbott J, Köller U, Haas OA, Hansen-Hagge T, Heil G, Seibt-Jung H, Teichmann JV, Ritter J, Knapp W, Gadner H, Thiel E, Riehm H. Phenotypic and genotypic heterogeneity in infant acute leukemia I. Acute lymphoblastic leukemia. Leukemia 1989; 3: 431-439.
15. Pui C-H, Hancock ML, Head DR, Rivera GK, Look AT, Sandlund JT, Behm FG. Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia. Blood 1993; 82: 889-894.
16. Pui C-H, Raimondi SC, Murphy SB, Ribeiro RC, Kalwinsky DK, Dahl GV, Crist WM, Williams DL. An analysis of leukemic cell chromosomal features in infants. Blood 1987; 69: 1289-1293.
17. Lampert F, Harbott J, Ritterbach J. Cytogenetic findings in acute leukaemias of infants. Br J Cancer 1992; 66 (Suppl. XVIII): S20-S22.
18. Cimino G, Lo Coco F, Biondi A, Elia L, Luciano A, Croce CM, Masera G, Mandelli F, Canaani E. ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. Blood 1993; 82: 544-546.
19. Chen C-S, Sorensen PHB, Domer PH, Reaman GH, Korsmeyer SJ, Heerema NA, Hammond GD, Kersey JH. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993; 81: 2386-2393.
20. Heerema NA, Arthur DC, Sather H, Albo V, Feusner J, Lange BJ, Steinherz PG, Zeltzer P, Hammond D, Reaman GH. Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Childrens Cancer Group. Blood 1994; 83: 2274-2284.
21. Rubnitz JE, Link MP, Shuster JJ, Carroll AJ, Hakami N, Frankel LS, Pullen DJ, Cleary ML. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 1994; 84: 570-573.
22. Cimino C, Rapanotti MC, Lo Coco F, D'Arcangelo E, Rondelli R, Basso G, Barisone E, Rosanda C, Santostasi T, Canaani E, Masera G, Mandelli F, Biondi A. Prognositc relevance of ALL-1 gene rearrangement in infant acute leukemias. Leukemia 1995; 9: 391-395.
23. Lampkin B, Buckley J, Nesbit M, Hammon D, Children's Cancer Study Group (CCSG). Clinical and laboratory findings and responses to therapy in infants less than one year of age with acute non-lymphocytic leukemia (ANLL). Proc Am Soc Clin Oncol 1984; 3: 201 (abstr.).
24. Pui C-H, Dahl GV, Kalwinsky DK, Look AT, Mirro J, Dodge RK, Simone JV. Central nervous system leukemia in children with acute nonlymphoblastic leukemia. Blood 1985; 66: 1062-1067.
25. van Wering ER, Kamps WA. Acute leukemia in infants. A unique pattern of acute nonlymphocytic leukemia. Am J Pediatr Hematol Oncol 1986; 8: 220-224.
26. Chessells JM, O'Callaghan U, Hardisty RM. Acute myeloid leukaemia in childhood: clinical features and prognosis. Br J Haematol 1986; 63: 555-564.
27. Grier H, Delorey M, Camitta B, Link M, Blattner S, Perrine S, Weinstein H. Acute myelogenous leukemia (AML) in infants. Proc Am Soc Clin Oncol 1987; 6: 154 (abstr.).
28. Pui C-H, Kalwinsky DK, Schell MJ, Mason CA, Mirro J Jr, Dahl GV. Acute nonlymphoblastic leukemia in infants: clinial presentation and outcome. J Clin Oncol 1988; 6: 1008-1013.
29. Köller U, Haas OA, Ludwig W-D, Bartram CR, Harbott J, Panzer-Grümayer R, Hansen-Hagge T, Ritter J, Creutzig U, Knapp W, Gadner H. Phenotypic and genotypic heterogeneity in infant acute leukemia. II. Acute nonlymphoblastic leukemia. Leukemia 1989; 3: 708-714.
30. Sorensen PHB, Chen C-S, Smith FO, Arthur DC, Domer PH, Berstein ID, Korsmeyer SJ, Hammond GD, Kersey JH. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Invest 1994; 93: 429-437.
31. Cimino C, Rapanotti MC, Elia L, Biondi A, Fizzotti M, Testi AM, Tosti S, Croce CM, Canaani E, Mandelli F, Lo Coco F. ALL-1 gene rearrangements in acute myeloid leukemia: association with M4-M5 French-American-British classification subtypes and young age. Cancer Res 1995; 55: 1625-1628.
32. Pui C-H, Simone JV, Hancock ML, Evans WE, Williams DL, Bowman WP, Dahl GV, Dodge RK, Ochs J, Abromowitch M, Rivera GK. Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St Jude Total Therapy Study X. Leukemia 1992; 6: 150-157.
33. Evans WE, Rodman J, Relling MV, Crom WR, Rivera GK, Crist WM, Pui C-H. Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol 1991; 28: 15-21.
34. Pui C-H, Relling MV, Behm FG, Hancock ML, Boyett JM, Raimondi SC, Krance RA, Mahmoud HH, Ribeiro RC, Sandlund JT, Head DR, Evans WE, Crist WM, Rivera GK. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995; 9: 1680-1684.
35. Hurwitz CA, Krance R, Schell MJ, Santana VM, Brenner MK, Ribeiro R, Roberts WM, Mahmoud H, Belt J, Crom W, Shearer PD, Mirro J Jr. Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital. Leukemia 1992; 6 (Suppl. 2): 39-43.
36. Pui C-H, Behm FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82: 343-362.
37. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 626-629.
38. Williams DL, Harris A, Williams KJ, Brosius MJ, Lemonds W. A direct bone marrow chromosome technique for acute lymphoblastic leukemia. Cancer Genet Cytogenet 1984; 13: 239-257.
39. ISCN (1991). Mitelman F (ed). Guidelines for Cancer Cytogenetics, Supplement to An International System for Human Cytogenetic Nomenclature. Karger: Basel, 1991, pp 1-54.
40. Manabe A, Murti KG, Coustan-Smith E, Kumagai M-a, Behm FG, Raimondi SC, Campana D. Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood 1994; 83: 758-766.
41. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
42. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.
43. Behm FG, Raimondi SC, Frestedt JL, Liu C, Crist WM, Downing JR, Rivera GK, Kersey JH, Pui C-H. Rearrangement of MLL confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood (in press).
44. Kaspers GJL, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leuk Lymphoma (in press).
45. Kumagai M, Manabe A, Pui C-H, Behm FG, Raimondi SC, Hancock M, Mahmoud H, Crist WM, Campana D. Stroma-supported culture of childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest 1996; 97: 755-760.
46. Raimondi SC, Frestedt JL, Pui C-H, Downing JR, Head DR, Kersey JH, Behm FG. Acute lymphoblastic leukemias with deletion of 11q23 or a novel inversion (11)(p13q23) lack MLL gene rearrangements and have favorable clinical features. Blood 1995; 86: 1881-1886.
47. Akao Y, Seto M, Yamamoto K, Iida S, Nakazawa S, Inazawa J, Abe T, Takahashi T, Ueda R. The RCK gene associated with t(11;14) translocation is distinct from the MLL/ALL-1 gene with t(4;11) and t(11;19) translocations. Cancer Res 1992; 52: 6083-6087.
48. Chen Z, Guidez F, Rousselot P, Agadir A, Chen S-J, Wang Z-Y, Degos L, Zelent A, Waxman S, Chomienne C. PLZF-RARα fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci USA 1994; 91: 1178-1182.
49. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD, Colan SD. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. New Engl J Med 1995; 332: 1738-1743.
50. Paz-Ares L, Dobbs N, Twelves C. Doxorubicin-induced cardiotoxicity. New Engl J Med 1995; 333: 1360.